We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Next generation biologics company Noveome Biotherapeutics will evaluate its lead programme ST266 as a potential treatment of severe cytokine storm response associated with Covid-19.